Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03253003
Other study ID # Sonova2017_27
Secondary ID
Status Completed
Phase N/A
First received August 14, 2017
Last updated September 21, 2017
Start date August 7, 2017
Est. completion date August 25, 2017

Study information

Verified date September 2017
Source Sonova AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A methodical evaluation of new CE-labelled Phonak Hearing Systems is intended to be conducted on hard of participants with a hearing loss to grant quality control prior to product launch. The aim of the investigation series is to ensure a stable overall performance of the new hearing systems, a good sound quality during phone calls as well as maximum benefit for the participant with the devices.


Description:

Phonak Hearing Systems pass through different development and study stages. At an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. If the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, as a result, they get optimized. Afterwards, and prior to product launch, the Phonak Hearing Systems undergo a final quality control in terms of clinical trials in the way as planned for this study ("phase of final inspection"). This will be a clinical evaluation which will be conducted mono centric at Sonova AG Headquarters based in Stäfa (Switzerland).


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date August 25, 2017
Est. primary completion date August 25, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria:

- Adult hearing impaired persons (minimum age: 18 years) with and without (experience with) hearing aids

- Good written and spoken (Swiss) German language skills

- Healthy outer ear

- Ability to fill in a questionnaire (p/eCRF) conscientiously

- Informed Consent as documented by signature

- Smartphone user

Exclusion Criteria:

- Contraindications to the MD in this study, e.g. known hypersensitivity or allergy to the investigational product

- Limited mobility and not in the position to attend weekly appointments in Stäfa (Switzerland)

- Limited ability to describe listening impressions/experiences and the use of the hearing aid

- Inability to produce a reliable hearing test result

- Massively limited dexterity

- Known psychological problems

- Central hearing disorders

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Line extension of the Phonak Audéo B product family
The line extension of Phonak Audéo B product family will be fitted to the participants individual hearing loss.

Locations

Country Name City State
Switzerland Sonova AG Stäfa Zürich

Sponsors (1)

Lead Sponsor Collaborator
Sonova AG

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Stable performance in daily life The data, serving as primary outcomes are collected in a series of home trials, taking place between the lab trial appointments. The stable performance in daily life (that means: no significant interruptions, distortions, artefacts, feedback, system noise or other malfunctions) will be assessed with the aid of quantitative questionnaires. Descriptive statistics will be executed. Interference statistics will be executed by applying the appropriate parametric or non-parametric test, depending on the data's distribution. A significance level of 5% is pursued. Three weeks
Primary Phone call - Sound Quality The data serving as primary outcomes are collected in a lab appointment. The participants will be asked to have a phone call with the investigator in the lab. The sound quality will be subjectively assessed by the participants and additionally by the investigators on given scales. Descriptive statistics will be executed. Interference statistics will be executed by applying the appropriate parametric or non-parametric test, depending on the data's distribution. A significance level of 5% is pursued. One week
See also
  Status Clinical Trial Phase
Recruiting NCT05525221 - Societal Merit of Intervention on Hearing Loss Evaluation
Completed NCT03131557 - Quality Control of CE-Certified Phonak Hearing Aids - 2017_13 N/A
Completed NCT03108768 - Quality Control of CE-Certified Phonak Hearing Aids - 2016_37 N/A